ESMO 2018 | CheckMate 032: nivolumab/ipilimumab for urothelial carcinoma
Jonathan Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses results from the Phase I/II CheckMate 032 trial (NCT01928394), where the nivolumab/ipilimumab combination was compared with nivolumab monotherapy in urothelial carcinoma. A higher dose of ipilimumab in the combination therapy seemed to result in improved anti-cancer activity compared to nivolumab alone; however, Dr Rosenberg advises caution as the data is immature. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
Get great new content delivered to your inboxSign up